Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Drug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 21, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...

Company Medical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Fineline Cube Apr 21, 2025

US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study

Fineline Cube Apr 21, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658

Fineline Cube Apr 21, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...

Company Drug

AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment

Fineline Cube Apr 21, 2025

China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...

Company Drug

Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone

Fineline Cube Apr 21, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...

Company Drug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

Fineline Cube Apr 18, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Fineline Cube Apr 18, 2025

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company Deals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Fineline Cube Apr 18, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...

Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Fineline Cube Apr 18, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...

Company Drug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Fineline Cube Apr 18, 2025

The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...

Company Deals

Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102

Fineline Cube Apr 18, 2025

Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into...

Company Drug

Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes

Fineline Cube Apr 18, 2025

U.S. pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has announced positive top-line results from...

Company Drug

3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China

Fineline Cube Apr 18, 2025

China-based 3SBio Inc. (HKG: 1530) has announced the receipt of Breakthrough Therapy Designation (BTD) from...

Company Deals

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development

Fineline Cube Apr 18, 2025

NeuShen Therapeutics, a biotech company with operations in Shanghai, China, and Boston, Massachusetts, has closed...

Company

La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone

Fineline Cube Apr 18, 2025

Switzerland-based Clinique La Prairie Holistic Health SA has received approval for its functional nutrient product...

Company Drug

GSK’s Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59

Fineline Cube Apr 18, 2025

UK-based pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK) has announced a favorable vote from the US...

Company Drug

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy

Fineline Cube Apr 18, 2025

China-based Gene Cradle has received approval from the National Medical Products Administration (NMPA) to proceed...

Company Medical Device

Medtronic’s Implantable Defibrillator System Gains NMPA Approval in China

Fineline Cube Apr 18, 2025

China’s National Medical Products Administration (NMPA) has approved Medtronic’s (NYSE: MDT) endovascular implantable defibrillation electrode...

Company Drug

Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study

Fineline Cube Apr 18, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...

Posts pagination

1 … 176 177 178 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.